Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.230
-0.060 (-4.65%)
At close: Jun 20, 2025, 4:00 PM
1.240
+0.010 (0.81%)
After-hours: Jun 20, 2025, 7:57 PM EDT

Allogene Therapeutics Stock Forecast

Stock Price Forecast

The 9 analysts that cover Allogene Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $8.44, which forecasts a 586.18% increase in the stock price over the next year. The lowest target is $4 and the highest is $14.

Price Target: $8.44 (+586.18%)
Analyst Consensus: Strong Buy
Target Low Average Median High
Price $4.00 $8.44 $9.00 $14
Change +225.20% +586.18% +631.71% +1038.2%
* Price targets were last updated on May 15, 2025.

Analyst Ratings

The average analyst rating for Allogene Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Jan '25Feb '25Mar '25Apr '25May '25Jun '25
Strong Buy 444444
Buy 555565
Hold 331100
Sell 000000
Strong Sell 000000
Total 12121010109

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Citigroup
Citigroup
Strong Buy
Maintains
$8$4
Strong Buy Maintains $8$4 +225.20% May 15, 2025
Truist Securities
Truist Securities
Strong Buy
Maintains
$14$10
Strong Buy Maintains $14$10 +713.01% May 14, 2025
Piper Sandler
Piper Sandler
Buy
Maintains
$9$7
Buy Maintains $9$7 +469.11% May 14, 2025
RBC Capital
RBC Capital
Buy
Reiterates
$10
Buy Reiterates $10 +713.01% May 14, 2025
Oppenheimer
Oppenheimer
Buy
Maintains
$10$9
Buy Maintains $10$9 +631.71% May 14, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
5.57K
from 22.00K
Decreased by -74.69%
Revenue Next Year
16.69K
from 5.57K
Increased by 199.63%
EPS This Year
-1.07
from -1.32
EPS Next Year
-1.02
from -1.07
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
-114.09M156.00K95.00K22.00K5.57K16.69K29.79M
Revenue Growth
---99.86%-39.10%-76.84%-74.69%199.63%178,408.08%
EPS
-2.63-1.34-2.38-2.09-1.32-1.07-1.02-1.19
EPS Growth
--------
Forward PE
--------
No. Analysts
-----171712
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 63,000 105,000 147.2M
Avg 5,569 16,687 29.8M
Low n/a n/a n/a

Revenue Growth

Revenue Growth 20252026202720282029
High
186.4%
1,785.4%
882,133.1%
Avg
-74.7%
199.6%
178,408.1%
Low - - -

EPS Forecast

EPS 20252026202720282029
High -0.78 -0.58 -0.87
Avg -1.07 -1.02 -1.19
Low -1.40 -1.44 -1.53

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.